103189-63-5

Basic information

• Product Name: 3-Amino-butyric acid methyl ester
• Synonyms: 3-Amino-butyric acid methyl ester;Butanoic acid, 3-aMino-, Methyl ester, (3R)-;(R)-3-AMinobutanoic acid Methyl ester;Butanoic acid, 3-aMino-, Methyl ester, (R)-;Methyl (3R)-aMinobutanoate;(R)-Methyl 3-aminobutanoate
• CAS NO: 103189-63-5
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Mol File: 103189-63-5.mol

Chemical Properties

• Boiling Point: 159.795°C at 760 mmHg
• Flash Point: 33.959°C
• Appearance: /
• Density: 0.988g/cm³
• Vapor Pressure: 2.46mmHg at 25°C
• Refractive Index: 1.427
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• PKA: 8.71±0.10(Predicted)
• CAS DataBase Reference: 3-Amino-butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-butyric acid methyl ester(103189-63-5)
• EPA Substance Registry System: 3-Amino-butyric acid methyl ester(103189-63-5)

Safety Data

• RIDADR: 3272
• HazardClass: 3
• PackingGroup: Ⅲ
• Hazardous Substances Data: 103189-63-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-butyric acid methyl ester is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to facilitate the production of N-unprotected β-amino esters. This allows for the development of new drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3-Amino-butyric acid methyl ester is used as a versatile building block for the creation of various organic molecules. Its reactivity and stereoselective properties make it an ideal candidate for the synthesis of complex molecules with specific configurations.
Used in Research and Development:
3-Amino-butyric acid methyl ester is utilized in research and development settings as a valuable tool for studying the properties and reactions of amino acids and their derivatives. Its unique characteristics enable scientists to explore new pathways and mechanisms in organic chemistry, potentially leading to breakthroughs in various fields.
Overall, 3-Amino-butyric acid methyl ester is a multifaceted compound with applications in the pharmaceutical, chemical synthesis, and research industries, thanks to its unique properties and reactivity.

InChI:InChI=1/C5H11NO2/c1-4(6)3-5(7)8-2/h4H,3,6H2,1-2H3/t4-/m1/s1

Upstream product

• 67-56-1 methanol 
• 3775-72-2 L-3-aminobutyric acid 
• 75-77-4 chloro-trimethyl-silane 
• 53118-62-0 (S)-3-((S)-1-Phenyl-ethylamino)-butyric acid methyl ester 
• 83460-84-8 methyl (3S)-3-{[(benzyloxy)carbonyl]amino}butanoate 
• 138474-81-4 dimethyl 2-<(1S)-1-(tert-butoxycarbonylamino)ethyl>malonate 
• 14205-39-1 methyl 3-aminocrotonate 
• 105-45-3 acetoacetic acid methyl ester 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 53118-62-0 (R)-3-((S)-1-Phenyl-ethylamino)-butyric acid methyl ester 
• 64838-60-4 (3R,1'S)-3-<(1'-phenylethyl)amino>butanoic acid methyl ester 
• 134430-97-0 methyl (3R,αR)-3-(N-benzyl-N-α-methylbenzylamino)butanoate 
• 678991-47-4 (-)-(3R)-methyl 3-(dibenzylamino)butanoate 

Downstream Products

• 3775-72-2 L-3-aminobutyric acid 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 58610-41-6 (3S)-3-aminobutanoic acid hydrochloride 
• 83460-87-1 (S)-3-((S)-3-Benzoylamino-butyrylamino)-butyric acid methyl ester 
• 83509-91-5 (S)-3-[(S)-3-((S)-3-Benzyloxycarbonylamino-butyrylamino)-butyrylamino]-butyric acid methyl ester 
• 83460-92-8 (S)-3-((S)-3-Benzyloxycarbonylamino-butyrylamino)-butyric acid methyl ester 
• 76904-98-8 (S)-3-((R)-3,3,3-Trifluoro-2-methoxy-2-phenyl-propionylamino)-butyric acid methyl ester 
• 142925-36-8 (S)-(+)-N-(3-phenylaminobutyryl)benzoic acid 
• 113034-32-5 methyl ester of (S)-3-(benzoylamino)butanoic acid 
• 61477-39-2 (+)-(S)-3-aminopropan-1-ol 
• 83460-84-8 methyl (3S)-3-{[(benzyloxy)carbonyl]amino}butanoate 
• 1228754-14-0 C₂₇H₃₅N₃O₄S 
• 1313618-76-6 C₁₆H₂₅N₃O₅S 
• 159877-47-1 methyl 3-(R)-[N-(tert-butoxycarbonyl)amino]-propanoate 

Relevant articles and documents

MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

The present invention relates to a macrocyclic compound as a CDK inhibitor, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a novel macrocyclic compound represented by a general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, the use thereof as a therapeutic agent, particularly as a CDK inhibitor, and the use thereof in treating cancers, inflammation, viral infections, cardiac hypertrophy or HIV, wherein each substituent of the general formula (I) is the same as that defined in the description.

Pathway from N-Alkylglycine to Alkylisonitrile Catalyzed by Iron(II) and 2-Oxoglutarate-Dependent Oxygenases

N-alkylisonitrile, a precursor to isonitrile-containing lipopeptides, is biosynthesized by decarboxylation-assisted -N≡C group (isonitrile) formation by using N-alkylglycine as the substrate. This reaction is catalyzed by iron(II) and 2-oxoglutarate (Fe/2OG) dependent enzymes. Distinct from typical oxygenation or halogenation reactions catalyzed by this class of enzymes, installation of the isonitrile group represents a novel reaction type for Fe/2OG enzymes that involves a four-electron oxidative process. Reported here is a plausible mechanism of three Fe/2OG enzymes, Sav607, ScoE and SfaA, which catalyze isonitrile formation. The X-ray structures of iron-loaded ScoE in complex with its substrate and the intermediate, along with biochemical and biophysical data reveal that -N≡C bond formation involves two cycles of Fe/2OG enzyme catalysis. The reaction starts with an FeIV-oxo-catalyzed hydroxylation. It is likely followed by decarboxylation-assisted desaturation to complete isonitrile installation.

Synthetic method of (R)-3- n-aminobutanol (by machine translation)

The invention belongs to, the field (R)- 3 - of pharmaceutical and chemical engineering, and particularly relates to a method for. preparing a product (R)- 3 - with good chemical purity, and optical, purity by, a, preparation method of a chiral drug midbody . (by machine translation)

Solid-phase synthesis and circular dichroism study of β-abpeptoids

The development of peptidomimetic foldamers that can form well-defined folded structures is highly desirable yet challenging. We previously reported on α-ABpeptoids, oligomers of N-alkylated β2-homoalanines and found that due to the presence of chiral methyl groups at α-positions, α-ABpeptoids were shown to adopt folding conformations. Here, we report β-ABpeptoids having chiral methyl group at β-positions rather than α-positions as a different class of peptoids with backbone chirality. We developed a facile solid-phase synthetic route that enables the synthesis of β-ABpeptoid oligomers ranging from 2-mer to 8-mer in excellent yields. These oligomers were shown to adopt ordered folding conformations based on circular dichroism (CD) and NMR studies. Overall, these results suggest that β-ABpeptoids represent a novel class of peptidomimetic foldamers that will find a wide range of applications in biomedical and material sciences.

METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE

A branched chain alkyl heteroaromatic ring derivative represented by formula (Ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (OX) receptor antagonist activity.

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

A multifaceted secondary structure mimic based on piperidine-piperidinones

Minimalist secondary structure mimics are typically made to resemble one interface in a protein-protein interaction (PPI), and thus perturb it. We recently proposed suitable chemotypes can be matched with interface regions directly, without regard for secondary structures. Here we describe a modular synthesis of a new chemotype 1, simulation of its solution-state conformational ensemble, and correlation of that with ideal secondary structures and real interface regions in PPIs. Scaffold 1 presents amino acid side-chains that are quite separated from each other, in orientations that closely resemble ideal sheet or helical structures, similar non-ideal structures at PPI interfaces, and regions of other PPI interfaces where the mimic conformation does not resemble any secondary structure. 68 different PPIs where conformations of 1 matched well were identified. A new method is also presented to determine the relevance of a minimalist mimic crystal structure to its solution conformations. Thus dld-1-faf crystallized in a conformation that is estimated to be 0.91 kcal-mol-1 above the minimum energy solution state. Do we know, when designing a new peptidomimetic scaffold like the one shown, how it can resemble secondary structures? Design and modular synthesis of this elongated mimic is reported, and the structure is related to ideal and real structures at PPI interfaces.

Efficient synthesis of β'-amino-α, β-unsaturated ketones

A general and simple procedure to access chiral β'-amino-α, β-enones, in seven steps, from an α,β unsaturated ester has been described. The use of a Horner-Wadsworth-Emmons reaction as a key step for generating the β'-amino-α,β-enones, permits access to a range of substrates under mild conditions and in moderate to high yield.